DUBLIN, Nov. 1, 2023 /PRNewswire/ — The “Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering.
The global antibody drug conjugates market is projected to reach USD 19.8 billion by 2028 from USD 9.7 billion in 2023, at a CAGR of 15.2% during the forecast period.
Factors such as the rising prevalence of cancer, robust products under clinical studies, and increased industrial collaborations are likely to drive market growth. For instance, in August 2023, ImmunoGen, Inc. entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.
The Kadcyla segment held the dominant share in the antibody drug conjugates market
Based on product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and others. The Kadcyla segment accounted for the largest share of the market in 2022. Extensive use of Kadcyla for breast cancer treatment is likely to drive the growth of the market. Recent approvals for various disease indications for Polivy and Adcertis are further likely to uplift the market in the coming years.
Breast cancer segment accounted for the largest share of the disease type segment in 2022
Based on disease type, the antibody drug conjugates market is segmented into breast cancer, lung cancer and other diseases. In 2022, the breast cancer segment accounted for the largest share of the antibody drug conjugates market. The segment held the dominant share in the market owing to various factors such as the increasing prevalence of breast cancer coupled with the rising demand for ADCs for breast cancer. The launch of biosimilar is further likely to have a positive impact on the market growth.
Asia-Pacific region is likely to grow at a faster pace
The antibody-drug conjugates market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Asia-Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for ADCs in China and Japan. The launch of the biosimilar Ujvira for the treatment of breast cancer in India is likely to give momentum to the market growth in the region.
Premium Insights
Rising Prevalence of Cancer to Drive Market Growth During Forecast Period
Breast Cancer Segment Accounted for Largest Share of North American Antibody Drug Conjugates Market in 2022
Kadcyla Segment to Dominate Market During Forecast Period
Asia-Pacific Countries to Register Higher Growth Rates from 2023 to 2028
Market Dynamics
Drivers
Rising Incidence of Cancer
Increasing Investments for ADC Development
Growing Number of ADCs in Clinical Trials
Favorable Regulatory Support
Restraints
High Manufacturing Costs
Side Effects Associated with ADCs
High Attrition Rate in Product Development
Opportunities
Adoption of Combination Therapies
High Growth in Emerging Economies
Emergence of Advanced ADCs
Challenges
Technical Complexities
Companies Mentioned
AbbVie Inc.
ADC Therapeutics SA
Ambrx
Astellas Pharma Inc.
AstraZeneca
Bionecure Therapeutics Inc.
Byondis
Daiichi Sankyo Company, Limited
Duality Biologics
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Immunogen, Inc.
Lanova Medicines
LegoChem Biosciences, Inc.
Lepu Biopharma Co. Ltd.
Mersana Therapeutics
Pfizer Inc.
ProfoundBio
Remegen
Seagen Inc.
Sutro Biopharma, Inc.
Takeda Pharmaceutical Company Limited
Tripartite Therapeutics, Inc.
Zydus Group
Zymeworks Inc.
Key Attributes:
|
Report Attribute |
Details |
|
No. of Pages |
273 |
|
Forecast Period |
2023 – 2028 |
|
Estimated Market Value (USD) in 2023 |
$9.7 Billion |
|
Forecasted Market Value (USD) by 2028 |
$19.8 Billion |
|
Compound Annual Growth Rate |
15.2 % |
|
Regions Covered |
Global |
For more information about this report visit https://www.researchandmarkets.com/r/955nm8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
